Nxera Pharma Ltd collects clinical US$35m milestone
Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Researchers present AI-guided protein design tool
/in News/by Thomas GabrielczykDanish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many properties afforded by protein disorder.
Amferia partners with Biokema expanding into Switzerland
/in News/by Thomas GabrielczykSwedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.
Confusion in Germany about useful genetic testing
/in News/by Thomas GabrielczykThe extent to which vested interests can delay innovation can currently be seen in the introduction of screening for the dominantly inherited disease familial hypercholesterolaemia, the benefits of which have already been proven in the UK and the Netherlands.
AI identifies most effective climate policies
/in News/by Thomas GabrielczykA brand-new AI analysis of 1,500 climate policies across 41 countries between 1998 and 2022 reveals that only 4% achieved significant emission reductions.
Vandria closes Series A round at CHF28.3m
/in News/by Thomas GabrielczykSwiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing.
Adcendo broadens ADC pipeline in US$1bn biobucks deal
/in News/by Thomas GabrielczykDanish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
Emfret presents novel anticoagulant
/in News/by Thomas GabrielczykGerman biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.
BioNTech: ADC study continues with conditions
/in News/by Thomas GabrielczykGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
Bavarian Nordic A/S applies for EU label extension of mpox vaccine
/in News/by Thomas GabrielczykDanish vaccine maker Bavarian Nordic A/S has submitted data to the EMA that support label extension of its mpox vaccine imvanex indication to include adolescents 12 to 17 years of age.